{"id":233,"date":"2025-09-19T09:28:36","date_gmt":"2025-09-19T09:28:36","guid":{"rendered":"https:\/\/www.lifescienceintellipedia.com\/blog\/?p=233"},"modified":"2025-09-19T09:28:37","modified_gmt":"2025-09-19T09:28:37","slug":"the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions","status":"publish","type":"post","link":"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/","title":{"rendered":"The Role of Regulatory Affairs Consulting in Complex Biosimilar Submissions"},"content":{"rendered":"\n<p>Biosimilars are changing the game in pharma, but let\u2019s be real\u2014getting them approved isn\u2019t simple. Unlike generics, you can\u2019t just copy the recipe and call it a day. There\u2019s a lot of comparability studies, detailed clinical data, and perfectly aligned regulatory paperwork. That\u2019s where <a href=\"https:\/\/www.lifescienceintellipedia.com\/regulatory-services.php\">regulatory affairs consulting services<\/a> comes in the picture.<\/p>\n\n\n\n<p>And here\u2019s the kicker: every region, FDA, EMA, India, ASEAN, has its own way of checking the boxes. Miss one, and you\u2019re looking at delays, rejections, and wasted money. That\u2019s why regulatory affairs consulting isn\u2019t just a \u201cnice to have.\u201d It\u2019s the GPS that guides your biosimilar through this maze without crashing into roadblocks.<\/p>\n\n\n\n<p>In this post, we\u2019ll break down why submissions are so tricky, where teams usually slip, and how regulatory experts can save you from expensive do-overs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Why Biosimilar Submissions Are So Complex?<\/strong><\/h2>\n\n\n\n<p>Biosimilars aren\u2019t generics. They\u2019re copies of biological drugs that are <em>similar<\/em>, not identical. Because biologics are made from living things, tiny differences in how they\u2019re made (cell lines, purification, glycosylation etc.) can affect safety and efficacy. So you have to show similarity in quality, safety, <em>and<\/em> efficacy.<\/p>\n\n\n\n<p>Regulatory rules vary a lot. What the EMA demands may not work for the FDA; CDSCO in India has its own requirements. Things like the reference product you pick, or whether certain tests or animal studies are needed, differ by region. That means one size doesn\u2019t fit all.<\/p>\n\n\n\n<p>You also need comparability studies and commitments after launch. That means:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Tests that compare biosimilar vs reference in lots of detail (analytical, functional, non-clinical)<\/li>\n\n\n\n<li>Clinical trials to show efficacy &amp; safety<\/li>\n\n\n\n<li>Plans to keep monitoring safety once drug is in real use<\/li>\n<\/ul>\n\n\n\n<p>Skipping any of this can cost time, money, or worse, lead to rejection.<\/p>\n\n\n\n<p>Regulatory affairs consulting works like guardrails. Experts help you turn these challenges into strategic checkpoints\u2014not just boxes you tick. You plan ahead for where different agencies will push back, where data gaps might show up, and what extra you\u2019ll need so your submission doesn\u2019t stall.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Global Biomilars Regulations<\/strong><\/h2>\n\n\n\n<p>Biosimilar rules aren&#8217;t the same everywhere. What works for FDA may trip you up with EMA, CDSCO, or ASEAN. Knowing the landscape saves you from big delays or rejection.<\/p>\n\n\n\n<p><strong>USA (FDA \/ BPCI Act):<\/strong><br>The FDA gives biosimilars a special path under Section 351(k). To pass, your drug has to be <em>\u201chighly similar\u201d<\/em> to the original, with no big differences in safety, purity, or potency. If you want the \u201cinterchangeable\u201d tag, you also need to prove patients can safely switch back and forth without problems.<\/p>\n\n\n\n<p><strong>Europe (EMA):<\/strong><br>Europe has one of the oldest and strongest biosimilar systems. They use a \u201ctotality of evidence\u201d approach\u2014basically, they look at everything together: lab tests, functional studies, and sometimes smaller clinical trials if the data already proves similarity. The EMA has been approving biosimilars since 2006, so there\u2019s a long track record to follow.<\/p>\n\n\n\n<p><strong>India and ASEAN:<\/strong><br>In India biosimilar rules were updated in 2016, and they are more like the WHO guidelines. There\u2019s still some flexibility\u2014like smaller trial sizes in certain cases. ASEAN countries, on the other hand, are still catching up. Each country has its own way of doing things, so dossier expectations and post-marketing rules can vary a lot.<\/p>\n\n\n\n<p>Different rules mean you might build a dossier that works for one region but fails in another. Big risk: rejection or extra data requests which kill timelines and cost extra.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Quick Look: Biosimilar Rules Across Regions<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Region\/Authority<\/strong><\/td><td><strong>Core Requirement<\/strong><\/td><td><strong>Unique Features<\/strong><\/td><td><strong>Common Pitfalls<\/strong><\/td><\/tr><tr><td>USA (FDA\/BPCI Act)<\/td><td>Must show biosimilar is \u201c<em>highly similar<\/em>\u201d with no meaningful differences in safety, purity, potency<\/td><td>Interchangeable biosimilar needs switching studies<\/td><td>Understanding the extra bar for interchangeability<\/td><\/tr><tr><td>EU (EMA)<\/td><td>\u201cTotality of evidence\u201d \u2013 analytical, functional, and limited clinical data<\/td><td>Most established pathway; many precedents since 2006<\/td><td>Assuming reduced trials apply to all cases<\/td><\/tr><tr><td>India (CDSCO)<\/td><td>Alignment with WHO, requires analytical + clinical studies<\/td><td>Some flexibility in trial size and scope<\/td><td>Assuming small trials always suffice<\/td><\/tr><tr><td>ASEAN (Various)<\/td><td>National regulators set rules; some follow WHO<\/td><td>Evolving capacity; local trial\/data expectations vary<\/td><td>Assuming harmonization \u2013rules differ by country<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How Regulatory Affairs Consulting Actually Helps Biosimilar Pathways?<\/strong><\/h2>\n\n\n\n<p>When you\u2019re doing biosimilars, just knowing biology isn\u2019t enough. Regulatory Affairs Consulting (that\u2019s \u201cexperts making sure your files pass\u201d) fills the gaps and puts guardrails in place.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Core Jobs of Regulatory Consultants<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gap Analysis<\/strong>: They look at what you\u2019ve already done vs what FDA, EMA, or local bodies want. Find missing data in CMC, safety, clinical plans. (See DDReg\u2019s gap analysis service)<\/li>\n\n\n\n<li><strong>Strategy Formulation:<\/strong> Decide whether you\u2019ll submit the dossier in CTD or eCTD, how your comparability package should look (how similar your biosimilar has to be in tests), and what non-clinical\/clinical studies you\u2019ll need.<\/li>\n\n\n\n<li><strong>Scientific Advice Meetings:<\/strong> Meet with authorities or prepare packages to ask them questions ahead of time. For example, EMA offers tailored scientific advice on biosimilar data packages, especially when some clinical trials might be scaled down.<\/li>\n\n\n\n<li><strong>Risk Management:<\/strong> Predict where you might get hit with regulatory issues\u2014like CMC data gaps, stability or process changes, or manufacturing site shifts. For example, CRLs (Complete Response Letters) often cite CMC deficiencies because of inconsistent process or missing stability studies.<\/li>\n<\/ul>\n\n\n\n<p>Consultants translate your science into \u201capproval-ready\u201d dossiers. Without them, you risk delayed reviews, rejections, or being asked for more data (which costs time &amp; money).<\/p>\n\n\n\n<p>They help you build the plan so every authority you aim to submit to sees what they expect. And because rules differ, consultants help harmonize your documents so they meet multiple agencies\u2019 expectations without you rewriting everything each time.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How Lifescience Intellipedia Supports Biosimilar Submissions?<\/h2>\n\n\n\n<p>Getting a biosimilar approved is hard enough\u2014you don\u2019t want to waste time guessing what regulators want. That\u2019s where Lifescience Intellipedia comes in.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Intelligence:<\/strong> We keep track of biosimilar rules worldwide. From FDA\u2019s strict standards to ASEAN\u2019s evolving guidelines, we know what has worked before and what hasn\u2019t. This helps you plan smarter and avoid surprises.<\/li>\n\n\n\n<li><strong>Chemxpert Database:<\/strong> Our platform connects biosimilar projects to the right suppliers and API makers. This matters because if your supply chain isn\u2019t strong, regulators will flag it. We give you data that saves you from weak links.<\/li>\n\n\n\n<li><strong>Consulting Services:<\/strong> Our team helps with dossier writing, gap analysis, and preparing for scientific advice meetings with agencies like EMA or CDSCO. Think of it as having someone who speaks \u201cregulatory language\u201d for you.<\/li>\n\n\n\n<li><strong>The Value for You:<\/strong> By using our mix of data and consulting, you cut down on costly re-submissions, move faster through reviews, and build a strategy that works across multiple regions\u2014not just one.<\/li>\n<\/ul>\n\n\n\n<p>Bottom line: we give you the tools and guidance to make biosimilar submissions less painful and more predictable.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Ready to take your biosimilar submission from risky to approval-ready?<\/strong><\/h4>\n\n\n\n<p><a href=\"https:\/\/www.lifescienceintellipedia.com\/\">Lifescience Intellipedia<\/a> brings you the mix of regulatory affairs consulting, real-time intelligence, and supplier insights you need. Don\u2019t gamble with delays or rejections\u2014get expert support that helps you clear hurdles the first time.<\/p>\n\n\n\n<p><strong><em>Talk to our team today and see how we can simplify your global biosimilar strategy.<\/em><\/strong><strong><em><\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biosimilars are changing the game in pharma, but let\u2019s be real\u2014getting them approved isn\u2019t simple. Unlike generics, you can\u2019t just copy the recipe and call it a day. There\u2019s a lot of comparability studies, detailed clinical data, and perfectly aligned regulatory paperwork. That\u2019s where regulatory affairs consulting services comes in the picture. And here\u2019s the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":235,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39],"tags":[38,81],"class_list":["post-233","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science-database","tag-lifescience-intellipedia","tag-regulatory-affairs-consulting-services"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Role of Regulatory Affairs Consulting in Complex Biosimilar Submissions - LifescienceIntellipedia<\/title>\n<meta name=\"description\" content=\"In this post, we\u2019ll break down why submissions are so tricky, where teams usually slip, and how regulatory experts can save you from expensive do-overs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Role of Regulatory Affairs Consulting in Complex Biosimilar Submissions - LifescienceIntellipedia\" \/>\n<meta property=\"og:description\" content=\"In this post, we\u2019ll break down why submissions are so tricky, where teams usually slip, and how regulatory experts can save you from expensive do-overs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/\" \/>\n<meta property=\"og:site_name\" content=\"LifescienceIntellipedia\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-19T09:28:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-19T09:28:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-content\/uploads\/2025\/09\/Role-of-Regulatory-Affairs-Consulting-in-Complex-Biosimilar-Submissions.png\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Patel\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Patel\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/\",\"url\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/\",\"name\":\"The Role of Regulatory Affairs Consulting in Complex Biosimilar Submissions - LifescienceIntellipedia\",\"isPartOf\":{\"@id\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-content\/uploads\/2025\/09\/Role-of-Regulatory-Affairs-Consulting-in-Complex-Biosimilar-Submissions.png\",\"datePublished\":\"2025-09-19T09:28:36+00:00\",\"dateModified\":\"2025-09-19T09:28:37+00:00\",\"author\":{\"@id\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/#\/schema\/person\/dd40e842e0a65662e5ce1d2e9bc2ce00\"},\"description\":\"In this post, we\u2019ll break down why submissions are so tricky, where teams usually slip, and how regulatory experts can save you from expensive do-overs.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/#primaryimage\",\"url\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-content\/uploads\/2025\/09\/Role-of-Regulatory-Affairs-Consulting-in-Complex-Biosimilar-Submissions.png\",\"contentUrl\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-content\/uploads\/2025\/09\/Role-of-Regulatory-Affairs-Consulting-in-Complex-Biosimilar-Submissions.png\",\"width\":700,\"height\":400,\"caption\":\"Role of Regulatory Affairs Consulting in Complex Biosimilar Submissions\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Role of Regulatory Affairs Consulting in Complex Biosimilar Submissions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/#website\",\"url\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/\",\"name\":\"Abhabio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/#\/schema\/person\/dd40e842e0a65662e5ce1d2e9bc2ce00\",\"name\":\"Sandeep Patel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6615854e7daf09d53a423dfbf1993a5227d31f747ff30f155081414ce4096675?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6615854e7daf09d53a423dfbf1993a5227d31f747ff30f155081414ce4096675?s=96&d=mm&r=g\",\"caption\":\"Sandeep Patel\"},\"url\":\"https:\/\/www.lifescienceintellipedia.com\/blog\/author\/sandeep-patel\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Role of Regulatory Affairs Consulting in Complex Biosimilar Submissions - LifescienceIntellipedia","description":"In this post, we\u2019ll break down why submissions are so tricky, where teams usually slip, and how regulatory experts can save you from expensive do-overs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/","og_locale":"en_US","og_type":"article","og_title":"The Role of Regulatory Affairs Consulting in Complex Biosimilar Submissions - LifescienceIntellipedia","og_description":"In this post, we\u2019ll break down why submissions are so tricky, where teams usually slip, and how regulatory experts can save you from expensive do-overs.","og_url":"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/","og_site_name":"LifescienceIntellipedia","article_published_time":"2025-09-19T09:28:36+00:00","article_modified_time":"2025-09-19T09:28:37+00:00","og_image":[{"width":700,"height":400,"url":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-content\/uploads\/2025\/09\/Role-of-Regulatory-Affairs-Consulting-in-Complex-Biosimilar-Submissions.png","type":"image\/png"}],"author":"Sandeep Patel","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sandeep Patel","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/","url":"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/","name":"The Role of Regulatory Affairs Consulting in Complex Biosimilar Submissions - LifescienceIntellipedia","isPartOf":{"@id":"https:\/\/www.lifescienceintellipedia.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/#primaryimage"},"image":{"@id":"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-content\/uploads\/2025\/09\/Role-of-Regulatory-Affairs-Consulting-in-Complex-Biosimilar-Submissions.png","datePublished":"2025-09-19T09:28:36+00:00","dateModified":"2025-09-19T09:28:37+00:00","author":{"@id":"https:\/\/www.lifescienceintellipedia.com\/blog\/#\/schema\/person\/dd40e842e0a65662e5ce1d2e9bc2ce00"},"description":"In this post, we\u2019ll break down why submissions are so tricky, where teams usually slip, and how regulatory experts can save you from expensive do-overs.","breadcrumb":{"@id":"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/#primaryimage","url":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-content\/uploads\/2025\/09\/Role-of-Regulatory-Affairs-Consulting-in-Complex-Biosimilar-Submissions.png","contentUrl":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-content\/uploads\/2025\/09\/Role-of-Regulatory-Affairs-Consulting-in-Complex-Biosimilar-Submissions.png","width":700,"height":400,"caption":"Role of Regulatory Affairs Consulting in Complex Biosimilar Submissions"},{"@type":"BreadcrumbList","@id":"https:\/\/www.lifescienceintellipedia.com\/blog\/the-role-of-regulatory-affairs-consulting-in-complex-biosimilar-submissions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lifescienceintellipedia.com\/blog\/"},{"@type":"ListItem","position":2,"name":"The Role of Regulatory Affairs Consulting in Complex Biosimilar Submissions"}]},{"@type":"WebSite","@id":"https:\/\/www.lifescienceintellipedia.com\/blog\/#website","url":"https:\/\/www.lifescienceintellipedia.com\/blog\/","name":"Abhabio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lifescienceintellipedia.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.lifescienceintellipedia.com\/blog\/#\/schema\/person\/dd40e842e0a65662e5ce1d2e9bc2ce00","name":"Sandeep Patel","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.lifescienceintellipedia.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6615854e7daf09d53a423dfbf1993a5227d31f747ff30f155081414ce4096675?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6615854e7daf09d53a423dfbf1993a5227d31f747ff30f155081414ce4096675?s=96&d=mm&r=g","caption":"Sandeep Patel"},"url":"https:\/\/www.lifescienceintellipedia.com\/blog\/author\/sandeep-patel\/"}]}},"_links":{"self":[{"href":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-json\/wp\/v2\/posts\/233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-json\/wp\/v2\/comments?post=233"}],"version-history":[{"count":1,"href":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-json\/wp\/v2\/posts\/233\/revisions"}],"predecessor-version":[{"id":236,"href":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-json\/wp\/v2\/posts\/233\/revisions\/236"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-json\/wp\/v2\/media\/235"}],"wp:attachment":[{"href":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-json\/wp\/v2\/media?parent=233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-json\/wp\/v2\/categories?post=233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lifescienceintellipedia.com\/blog\/wp-json\/wp\/v2\/tags?post=233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}